)
Visual24 Oct 2025
The rise of Alphabet
Verona Pharma (VRNA) investor relations material
Verona Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Entered into a $10 billion acquisition agreement with Merck, expected to close in Q4 2025, subject to customary approvals.
Ohtuvayre (ensifentrine) approved by FDA for COPD in June 2024; U.S. launch began August 2024.
Submitted marketing applications for Ohtuvayre in the UK and EU in mid-2025.
Net income of $11.9 million for Q2 2025, first profitable quarter; accumulated deficit $567.1 million as of June 30, 2025.
Ongoing dispute with Nuance Pharma over buy-back of Greater China license; discussions ongoing.
Financial highlights
Q2 2025 revenue: $103.1 million, driven by $102.9 million in Ohtuvayre product sales.
Six months ended June 30, 2025: $179.4 million total revenue, $174.2 million from product sales.
Q2 2025 operating income: $13.3 million, compared to a $68.4 million loss in Q2 2024.
Cash and cash equivalents: $438.0 million as of June 30, 2025, up from $399.8 million at year-end 2024.
Selling, general and administrative expenses rose to $72.1 million in Q2 2025, up $23.1 million year-over-year, mainly due to commercial launch costs and share-based compensation.
Outlook and guidance
Cash, anticipated product sales, and available term loan funding expected to cover operating and capital needs for at least 12 months.
Future term loan advances contingent on commercial milestones and lender discretion.
If Merck transaction does not close, may seek to license Ohtuvayre outside the U.S. and require additional funding.
Merck deal termination fee impact?
Ohtuvayre sales concentration risk?
Nuance Pharma buy-back dispute implications?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Verona Pharma earnings date
Q3 20253 Nov, 2025
Next Verona Pharma earnings date
Q3 20253 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Verona Pharma plc is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of respiratory diseases. Its main product, ensifentrine, is designed to alleviate symptoms and improve health outcomes in conditions such as chronic obstructive pulmonary disease (COPD). The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage